Cargando…

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy

T cell infiltration and proliferation in tumor tissues are the main factors that significantly affect the therapeutic outcomes of cancer immunotherapy. Emerging evidence has shown that interferon-gamma (IFNγ) could enhance CXCL9 secretion from macrophages to recruit T cells, but Siglec15 expressed o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaodi, Zhang, Qi, Liang, Yixia, Xiong, Shiyu, Cai, Yan, Cao, Jincheng, Xu, Yanni, Xu, Xiaolin, Wu, Ye, Lu, Qiang, Xu, Xiaoding, Luo, Baoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692376/ https://www.ncbi.nlm.nih.gov/pubmed/38045048 http://dx.doi.org/10.1016/j.apsb.2023.07.012

Ejemplares similares

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy
por: He, Fei, et al.
Publicado: (2021)

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
por: Wang, Jun, et al.
Publicado: (2019)

Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis
por: Shen, Qian, et al.
Publicado: (2022)

Innovative signature establishment using lymphangiogenesis-related lncRNA pairs to predict prognosis of hepatocellular carcinoma
por: Cao, Jincheng, et al.
Publicado: (2022)

Nanoparticles (NPs)-mediated lncBCMA silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis
por: Yang, Ke, et al.
Publicado: (2023)

Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)‐Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib
por: Li, Senlin, et al.
Publicado: (2023)

Blocking siglec-10(hi) tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma
por: Xiao, Nan, et al.
Publicado: (2021)

Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas
por: Wang, Jinchao, et al.
Publicado: (2023)

Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022)

Siglec-15 promotes progression of clear renal cell carcinoma
por: Yang, Wen-Bo, et al.
Publicado: (2021)

Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
por: Ren, Xiubao
Publicado: (2019)

CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy
por: Barkal, Amira A, et al.
Publicado: (2019)

Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
por: Rodriguez, Ernesto, et al.
Publicado: (2021)

Siglec-15 Is an Immune Suppressor and Potential Target for Immunotherapy in the Pre-Metastatic Lymph Node of Colorectal Cancer
por: Du, Hang, et al.
Publicado: (2021)

Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles
por: Chong, Lijuan, et al.
Publicado: (2023)

Targeted therapy of rheumatoid arthritis via macrophage repolarization
por: Zhou, Xu, et al.
Publicado: (2021)

Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma
por: Chen, Quan, et al.
Publicado: (2023)

Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells
por: Sheng, Kaiqin, et al.
Publicado: (2023)

Identification of a Siglec-F+ granulocyte-macrophage progenitor
por: Bolden, Jessica E., et al.
Publicado: (2018)

Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma
por: Anand, Namrata, et al.
Publicado: (2023)

Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy
por: Yu, Yingyan, et al.
Publicado: (2023)

Nanoparticles (NPs)‐Meditated LncRNA AFAP1‐AS1 Silencing to Block Wnt/β‐Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy
por: Bi, Zhuofei, et al.
Publicado: (2020)

Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma
por: Hou, Xiaofeng, et al.
Publicado: (2022)

Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma
por: Zhao, Ju, et al.
Publicado: (2022)

Siglec Ligands
por: Gonzalez-Gil, Anabel, et al.
Publicado: (2021)

Integrative Analysis of Siglec-15 mRNA in Human Cancers Based on Data Mining
por: Li, Qiu-ting, et al.
Publicado: (2020)

Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases
por: Angata, Takashi
Publicado: (2020)

Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis
por: Dewi, Intan M.W., et al.
Publicado: (2021)

Targeting PI3Kγ/AKT Pathway Remodels LC3‐Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation
por: Liu, Xiaodi, et al.
Publicado: (2022)

Molecular cloning of porcine Siglec-3, Siglec-5 and Siglec-10, and identification of Siglec-10 as an alternative receptor for porcine reproductive and respiratory syndrome virus (PRRSV)
por: Xie, Jiexiong, et al.
Publicado: (2017)

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
por: Li, Guan-Zhang, et al.
Publicado: (2019)

The Role of Siglec-1 and SR-BI Interaction in the Phagocytosis of Oxidized Low Density Lipoprotein by Macrophages
por: Xiong, Yi-song, et al.
Publicado: (2013)

Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy
por: Dong, Zhihui, et al.
Publicado: (2023)

Differently Charged Super-Paramagnetic Iron Oxide Nanoparticles Preferentially Induced M1-Like Phenotype of Macrophages
por: Zhang, Wenyue, et al.
Publicado: (2020)

Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
por: Hayakawa, Toshiyuki, et al.
Publicado: (2017)

Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters
por: Quirino, Michael Williams Leal, et al.
Publicado: (2021)

Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

Preferential use of Siglec-1 or Siglec-10 by type 1 and type 2 PRRSV strains to infect PK15(S1–CD163) and PK15(S10–CD163) cells
por: Xie, Jiexiong, et al.
Publicado: (2018)

Anti–phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy
por: Zheng, Chunxiong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s2sdg3v8tgisid3t311fhcmnm4